- Tytuł:
- Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
- Autorzy:
- Źródło:
- Targeted Oncology; Jun2015, Vol. 10 Issue 2, p277-286, 10p
Czasopismo naukowe